Brainstorm Cell Therapeutics (BCLI) Stock Hits One-Year High Today

NEW YORK ( TheStreet) -- Shares of Brainstorm Cell Therapeutics (BCLI) surged more than 75% to a 52-week high of $8.47 on Fridayahead of the biotech company's data release on Monday.

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

Exclusive Report: Jim Cramer's Best Stocks for 2015

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Read more from the original source:

Brainstorm Cell Therapeutics (BCLI) Stock Hits One-Year High Today

Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars

NEW YORK (TheStreet) -- Shares ofNeuralstem (CUR) continue to rise, up 6.25% to $2.89, in morning trading Friday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI) , which touched a one-year high on Friday.

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

See the original post here:

Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars

One Reason Neuralstem (CUR) Stock is Rising Today

NEW YORK (TheStreet) -- Shares of stem cell therapy developerNeuralstem (CUR) rose 4.62% to $2.72 on higher-than-average volume in afternoon trading Wednesday in sympathy with peer companyBrainstorm Cell Therapeutics (BCLI) .

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

Exclusive Report: Jim Cramers Best Stocks for 2015

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Read more here:

One Reason Neuralstem (CUR) Stock is Rising Today

Brainstorm Cell Therapeutics (BCLI) Stock Rises Ahead of ALS Treatment Trial Data Release

NEW YORK (TheStreet) -- Shares ofBrainstorm Cell Therapeutics (BCLI) soared 20.88% to $4.69 on higher-than-average volume in morning trading Wednesday ahead of the biotech company's data release on Monday.

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

Exclusive Report: Jim Cramers Best Stocks for 2015

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

See the article here:

Brainstorm Cell Therapeutics (BCLI) Stock Rises Ahead of ALS Treatment Trial Data Release

Multiple sclerosis treatment: Stem cell transplant may …

An experimental treatment that uses a patient's own stem cells may offer new hope for people with multiple sclerosis.

In a small clinical trial, patients experienced long-term disease remission after undergoing a transplant of their own hematopoietic stem cells. This type of cell is responsible for the formation of blood in the body and are typically derived from bone marrow. The patients also took high-dose immunosuppressive drugs.

The paper, published Monday in JAMA Neurology, reports on the third year of a five-year study. A total of 24 patients with active relapsing-remitting MS were enrolled in the trial. With this type of MS, patients have points when their disease is active followed by periods when they do not experience any symptoms.

Play Video

Dr. Jon LaPook goes inside the trial and approval process for an experimental treatment using stem cells designed to make Multiple Sclerosis pati...

The researchers found that nearly 79 percent of the patients who underwent the procedure sustained full neurologic function for the three years following the treatment and symptoms of their disease did not progress. Additionally, patients in that time period did not develop any new lesions related to their disease.

More than 90 percent of patients did not experience disease progression, while 86 percent did not have any periods of relapse. Though a small number of patients did have side effects from the immunosuppressive drugs, they were no different than the side effects typically experienced by MS patients taking the drugs who haven't undergone stem cell therapy.

"Longer follow-up is needed to determine the durability of the response," the authors write in the study. "Careful comparison of the results of this investigation and other ongoing studies will be needed to identify the best approaches for high-dose immunosuppressive therapies for MS and plan the next clinical studies."

The authors of an accompanying editorial say the research indicates this type of therapy has potential to work on patients who do not experience disease remission with medications alone, such as immunosuppressive drugs and anti-inflammatory drugs such as corticosteroids.

However, they add that "the jury is still out regarding the appropriateness and indication" of stem cell transplants for MS patients. Stem cell therapy is not approved by the U.S. Food and Drug Administration for the treatment of MS. The National Multiple Sclerosis Society currently funds 15 research projects on stem cell therapies that have the potential to prevent disease activity and repair nerve damage.

View post:

Multiple sclerosis treatment: Stem cell transplant may ...

Stem Cell Therapy for MS Shows Promise | Stem Cells Therapy

Experimental treatment kills off, then resets the immune system

WebMD News from HealthDay

By Dennis Thompson

HealthDay Reporter

MONDAY, Dec. 29, 2014 (HealthDay News) An experimental therapy that kills off and then resets the immune system has given three years of remission to a small group of multiple sclerosis patients, researchers say.

About eight in 10 patients given this treatment had no new adverse events after three years. And nine in 10 experienced no progression or relapse in their MS, said lead author Dr. Richard Nash of the Colorado Blood Cancer Institute at Presbyterian/St. Lukes Medical Center in Denver.

I think we all think of this as a viable therapy, Nash said. We still need to perform a randomized clinical trial, but were all pretty impressed so far, in terms of what weve seen.

In multiple sclerosis, the bodys immune system for some unknown reason attacks the nervous system, in particular targeting the insulating sheath that covers the nerve fibers, according to the U.S. National Institutes of Health. People with the more common form, called relapsing-remitting MS, have attacks of worsening neurologic function followed by partial or complete recovery periods (remissions).

Over time, as the damage mounts, patients become physically weak, have problems with coordination and balance, and suffer from thinking and memory problems.

This new therapy seeks to reset the immune system by killing it off using high-dose chemotherapy, then restarting it using the patients own blood stem cells. Doctors harvest and preserve the patients stem cells before treatment, and re-implant them following chemotherapy.

Read the original here:

Stem Cell Therapy for MS Shows Promise | Stem Cells Therapy

Autologous Stem Cell / Bone Marrow Transplant (AutoSCT …

TOPICS About Autologous Phases |Q&A | Resources | Research News

PubMed TOPIC SEARCH: Review | Therapies | ASCO | Medscape (free login req.)

The Oncologist: Less is More: The Role of Purging in Hematopoietic Stem Cell Transplantation

It is likely that the benefit of purging will be dependent upon the tumor type and stage of disease, as well as the degree of purging possible in the individual case. To date, most trials in which progression-free and overall survival have been evaluable have been in hematological malignancies. A six-year single center study showed no benefit of purging in patients with non-Hodgkins lymphoma [53], nor did a large study from EBMT [15].

A stem cell transplant* may sometimes be medically necessary for patients with lymphomas. With a stem cell transplant, the stem cells** obtained from bone marrow, peripheral blood, or umbilical cord blood are given back to the patient following high dose treatment, which can damage or ablate (kill off) these vital cells.The engrafted stem cells can then restore bone marrow function** impaired or destroyed by the high dose conditioning therapy.

A stem cell transplant is sometimes called a bone marrow transplant.

* The terms stem cell transplant, infusion, rescue, engraftment, or support may be used interchangeably and essentially have the same meaning.

** Stem cells are immature cells known as hematopoietic or blood-forming stem cells. Hematopoietic stem cells divide to form more blood-forming stem cells, or they mature into one of three types of blood cells: white blood cells, which fight infection; red blood cells, which carry oxygen; and platelets, which help the blood to clot. Most hematopoietic stem cells are found in the bone marrow, but some cells, called peripheral blood stem cells (PBSCs), are found in the bloodstream. Blood in the umbilical cord also contains hematopoietic stem cells. Cells from any of these sources can be used in transplants [in order to restore bone marrow function.] Cancer.gov

The different types of stem cell transplants are named from the origin of the stem cells:

autologous stem cells harvested from self

Original post:

Autologous Stem Cell / Bone Marrow Transplant (AutoSCT ...

Houston-based company leads nation in medical wave of the future

When Pearland residents Todd and Linsey Hyatts son, Tucker Beau, received a diagnosis of Juvenile Rheumatoid Arthritis when he was just two years old, the future looked agonizing for the previously precocious little boy. His parents refused to lose hope, however, and took a chance on stem cell therapy to improve Tuckers quality of life.

Now at age six, Tucker Beau looks and acts like any other normal boy his age, save for taking rests more often. He has had two separate stem cell infusions in August and November that have turned his slow, painful decline into a fading memory.

Celltex Therapeutics Corp., a Houston-based biotechnology company located in the Galleria area, uses proprietary technology to isolate, multiply and store their clients own stem cells to be used for regenerative therapy. This therapy has been proven effective with many conditions, including vascular (e.g. Raynauds Disease, kidney artery disease), autoimmune (e.g. arthritis, multiple sclerosis, lupus) and degenerative (e.g. Parkinsons, Alzheimers) diseases.

To get stem cells for a client, fat is extracted from the abdomen in a minimally invasive process that takes 15 30 minutes with no recovery time. This fat is then taken to Celltex, where the components of the fat are separated.

Celltex isolates the mesenchymal stem cells (MSCs) and places them in a nutrient-rich environment to grow. The initial extraction contains about 250,000 stem cells. Celltexs methods can produce one billion cells from that original extraction in as little as 5 weeks, making it unnecessary for clients to have a second extraction in most cases. The cells are frozen and banked at Celltexs lab, ready if and when the client needs another infusion, whether that is in three months or 30 years.

Adult [as opposed to embryonic] MSCs have the remarkable potential of migrating to different parts of the body, recognizing sites of injury and inflammation, and are then able to transform into many different types of cells, says Celltex Chairman and CEO David Eller.

Celltex takes great care in providing safe, pure cells to their clients. The Quality Control Dept,, headed up by QC Manager Kathy Gohlke, tests the cells at different stages throughout the process to ensure that no contaminants are present and that the cells are healthy and viable. Should contaminants be found at some point, which has only happened once out of about 500 clients served since 2011, a second fat extraction may be required.

Erik Eller, Head of Operations, explained that Celltex is also prepared for all kinds of negative scenarios so that the banked cells will stay safe. In the event of a long-term power failure, large generators located on site automatically provide electricity for up to two weeks. An even longer-term solution is in the works. The actual vats that the cells are stored in do not require electricity at all.

The labs at Celltex contain two clean rooms; one for manufacturing and another for Quality Control. These rooms are kept at a constant and optimal temperature, are pressure controlled and the air is continuously filtered through hospital-grade HEPA filters to reduce the chances of contamination. Employees who work in the clean rooms must be covered from head to toe in protective gear to keep the stem cells as healthy as possible.

When a client is ready for treatment, Celltex ships that persons harvested stem cells to either Guadalajara or Cancun Mexico, where the client will receive the infusion in a top-of-the-line hospital by a licensed physician.

Continue reading here:

Houston-based company leads nation in medical wave of the future

Stem Cell Therapy for MS Shows Promise

Experimental treatment kills off, then 'resets' the immune system

WebMD News from HealthDay

By Dennis Thompson

HealthDay Reporter

MONDAY, Dec. 29, 2014 (HealthDay News) -- An experimental therapy that kills off and then "resets" the immune system has given three years of remission to a small group of multiple sclerosis patients, researchers say.

About eight in 10 patients given this treatment had no new adverse events after three years. And nine in 10 experienced no progression or relapse in their MS, said lead author Dr. Richard Nash of the Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center in Denver.

"I think we all think of this as a viable therapy," Nash said. "We still need to perform a randomized clinical trial, but we're all pretty impressed so far, in terms of what we've seen."

In multiple sclerosis, the body's immune system for some unknown reason attacks the nervous system, in particular targeting the insulating sheath that covers the nerve fibers, according to the U.S. National Institutes of Health. People with the more common form, called relapsing-remitting MS, have attacks of worsening neurologic function followed by partial or complete recovery periods (remissions).

Over time, as the damage mounts, patients become physically weak, have problems with coordination and balance, and suffer from thinking and memory problems.

This new therapy seeks to reset the immune system by killing it off using high-dose chemotherapy, then restarting it using the patient's own blood stem cells. Doctors harvest and preserve the patient's stem cells before treatment, and re-implant them following chemotherapy.

Read more:

Stem Cell Therapy for MS Shows Promise

Stem cell transplant may help patients with MS

An experimental treatment that uses a patient's own stem cells may offer new hope for people with multiple sclerosis.

In a small clinical trial, patients experienced long-term disease remission after undergoing a transplant of their own hematopoietic stem cells. This type of cell is responsible for the formation of blood in the body and are typically derived from bone marrow. The patients also took high-dose immunosuppressive drugs.

The paper, published Monday in JAMA Neurology, reports on the third year of a five-year study. A total of 24 patients with active relapsing-remitting MS were enrolled in the trial. With this type of MS, patients have points when their disease is active followed by periods when they do not experience any symptoms.

Play Video

Dr. Jon LaPook goes inside the trial and approval process for an experimental treatment using stem cells designed to make Multiple Sclerosis pati...

The researchers found that nearly 79 percent of the patients who underwent the procedure sustained full neurologic function for the three years following the treatment and symptoms of their disease did not progress. Additionally, patients in that time period did not develop any new lesions related to their disease.

More than 90 percent of patients did not experience disease progression, while 86 percent did not have any periods of relapse. Though a small number of patients did have side effects from the immunosuppressive drugs, they were no different than the side effects typically experienced by MS patients taking the drugs who haven't undergone stem cell therapy.

"Longer follow-up is needed to determine the durability of the response," the authors write in the study. "Careful comparison of the results of this investigation and other ongoing studies will be needed to identify the best approaches for high-dose immunosuppressive therapies for MS and plan the next clinical studies."

The authors of an accompanying editorial say the research indicates this type of therapy has potential to work on patients who do not experience disease remission with medications alone, such as immunosuppressive drugs and anti-inflammatory drugs such as corticosteroids.

However, they add that "the jury is still out regarding the appropriateness and indication" of stem cell transplants for MS patients. Stem cell therapy is not approved by the U.S. Food and Drug Administration for the treatment of MS. The National Multiple Sclerosis Society currently funds 15 research projects on stem cell therapies that have the potential to prevent disease activity and repair nerve damage.

Read more here:

Stem cell transplant may help patients with MS

More about Gordie Howe's therapy

Stem cells grown under low oxygen. These stem cells from Stemedica are licensed to CardioCell.

Dr. David Gorski, a prominent skeptic of therapies offered outside the scientifically controlled clinical trial system, has published an extensive and critical look at the stem cell therapy Gordie Howe received in early December to help him recover from a serious stroke.

I had email exchanges with Gorski while writing my article last week on the treatment, which uses stem cells provided by San Diego-based Stemedica. Gorski, whose previous blog post at Science-Based Medicine on Howe's treatment caught my attention, follows through with an analysis of the clinical trial setup used by Novastem, a Mexican stem cell company licensed by Stemedica to use its cells.

Dr. Murray Howe and his hockey great father, Gordie Howe, on a fishing trip in Saskatchewan in 2013. / Courtesy Murray Howe

"As sympathetic as I am to the Howe family, Im sorry. I reluctantly have to say that Murray Howe really should know better," Gorski wrote. "If Gordie Howe was treated as part of a clinical trial, then Novastem should have treated him for free! Thats because if it is running a clinical trial, it should treat everyone on the trial for free. Thats the way its done ethically."

I asked Novastem president Rafael Carrillo about the financial issue for my article. Carrillo said Novastem doesn't have deep pockets like a big pharmaceutical company, so it needs to charge for the treatment to pay its expenses. Without that money, it can't afford the trial. Patients wouldn't get the opportunity to get care that could help them, Carrillo said. Moreover, this arrangement is legal under Mexican law.

Gorksi views this as unethical, even if it's legal. He objects to the free treatment given to Gordie Howe, because it amounts to publicity for Novastem that will attract paying customers. And even if Howe is doing better, as appears to be the case, it's not possible to tell definitively whether stem cells helped.

The U.S. system has its own flaws, Gorski says, because patient expenses not related to the clinical trial are not paid for.

"Patients who dont have health insurance will often have a huge difficulty paying for their care not related to the clinical trial and thus will have difficulties accessing cutting-edge clinical trials because they cant pay for their own regular care," Gorski wrote. "Yay, USA!"

Stemedica is offering its own U.S. trial of the therapy, but people must have had the stroke at least six months ago. That's because people make the most improvement within six months after a stroke. So delaying treatment until after that point will make it easier to detect improvement caused by the stem cell treatment.

More here:

More about Gordie Howe's therapy

Stem cell registry will make cancer treatment cheaper

NEW DELHI: India may soon have an official database on stem cell donors and recipients. The health ministry is evaluating a proposal along with All India Institute of Medical Sciences (AIIMS) to create a donor registry as part of the National Health Mission (NHM), a senior official told TOI.

The proposal suggests enrolling all district hospitals in the first phase to seek stem cell details from across the country. "Once a stem cell donor registry is in place, a willing donor can be contacted and one can coordinate easily. Also, this would enhance access to safe blood," the official said.

Stem cells, found in bone marrow, are like building blocks which can grow into any normal cell of the body such as red blood cells to carry oxygen, white blood cells to fight infection, or platelets to stop bleeding.

Apart from the donor registry, the ministry is also looking at creating facilities for human leucocyte antigen (HLA) typing. HLA-typing is a process conducted for matching donors and recipients of stem cell. HLA-typing is necessary to minimize rejection of stem cell transplant, experts say.

Once created, this would be the first government registry in the country. Till now, such registries have been run in the country by a few NGOs such as Bharat Stem Cells.

According to Bharat Stem Cells, there is usually 25% chance of a patient finding a matching donor within the family. The rest depend on unrelated voluntary stem cell donors.

Stem cell therapy has been shown to be effective in various blood disorders and in treatment of cancer. It is widely used in bone marrow transplantation. However, stem cell treatment remains expensive because of limited research as well as unavailability and lack of coordination between donors and recipients. Some private hospitals charge as much as Rs 1 lakh per session for stem cell therapy. On an average, stem cell treatment is estimated to cost around Rs 15-16 lakh.

According to the official, the idea behind including stem cell into NHM is to make it affordable by creating records and providing facilities.

Stay updated on the go with The Times of Indias mobile apps. Click here to download it for your device.

Excerpt from:

Stem cell registry will make cancer treatment cheaper

Las Vegas Pain Management Clinic, Nevada Pain, Now Offering Over Ten Effective Treatments for Knee Arthritis with …

Las Vegas, Nevada (PRWEB) December 29, 2014

Top Las Vegas pain management clinic, Nevada Pain, is now providing over ten effective knee arthritis treatments. New treatments include regenerative medicine therapies such as PRP and stem cell therapy. Call (702) 323-0553 for more information and scheduling.

Knee arthritis affects tens of millions of Americans, often leading to significant disability. This may make it difficult to participate in recreational activities or play with one's kids or grandkids. While a total joint replacement typically has excellent outcomes, there are potential serious complications. Therefore, the procedure should be avoided or delayed until all other options have been attempted.

Nevada Pain offers the latest, cutting edge options for knee arthritis relief. This includes platelet rich plasma therapy, known as PRP therapy, along with stem cell therapy. The stem cell therapy is offered with either bone marrow derived stem cells or amniotic derived stem cells.

Additional treatments for knee arthritis include cortisone injections, which have been a gold standard for decades. They may provide months of consistent pain relief. Hyaluronic acid injections into the arthritic knee have been shown to offer six to twelve months of pain relief to most individuals.

Knee bracing is also offered along with TENS units, physical rehabilitation, pain medications and topical pain creams. Success rates are impressive for achieving pain relief and avoiding knee surgery.

Along with treating knee arthritis pain, Nevada Pain offers therapies for all types of back and neck pain, sciatica, scoliosis, neuropathy, RSD, spinal stenosis and much more. Treatment is offered by Board Certified, Award Winning providers.

Most insurance is accepted and there are multiple locations in the greater Las Vegas area. Call (702) 323-0553 for more information and scheduling.

More here:

Las Vegas Pain Management Clinic, Nevada Pain, Now Offering Over Ten Effective Treatments for Knee Arthritis with ...

ARTAS FUE Hair Transplant with Stem Cell Therapy at 1 year post-op – Video


ARTAS FUE Hair Transplant with Stem Cell Therapy at 1 year post-op
Amazing results after a FUE hair transplant by Dr. Yates with 2000 grafts using the newest ARTAS Robotic technology and newest therapy for hair restoration - Stromal Vascular Fraction Fat Transfer....

By: William Yates

See the article here:

ARTAS FUE Hair Transplant with Stem Cell Therapy at 1 year post-op - Video

Did stem cells really help Gordie Howe?

Dr. Murray Howe and his hockey great father, Gordie Howe, on a fishing trip in Saskatchewan in 2013.

Hockey legend Gordie Howe is making a dramatic recovery from a serious stroke thanks to stem cell therapy developed by San Diego-based Stemedica, his family says. Some medical scientists aren't so sure, however.

Howe, 86, suffered the stroke in late October, leaving him unable to walk and disoriented. He began improving within hours after receiving the stem cells in early December, said Dr. Murray Howe, a radiologist and one of Howes sons. For example, Howe insisted on walking to the bathroom, which he previously could not do.

"If I did not witness my father's astonishing response, I would not have believed it myself," Murray Howe said by email Thursday. "Our father had one foot in the grave on December 1. He could not walk, and was barely able to talk or eat."

"Our father's progress continues," the email continued. "Today, Christmas, I spoke with him on FaceTime. I asked him what Santa brought him. He said 'A headache.' I told him I was flying down to see him in a week. He said, 'Thanks for the warning.'"

Howe is receiving speech and physical therapy at his home in Lubbock, Texas, and his therapists say he is much better than before receiving the stem cells.

Howe received the treatment from Novastem, a Mexican stem cell company that has licensed the use of Stemedica's cells for clinical trials approved by the Mexican government. Howe was given neural stem cells to help his brain repair damage, and stem cells derived from bone marrow to improve blood circulation in the brain. The procedure took place at Novastem's Clinica Santa Clarita in Tijuana.

Such use of unproven stem cell therapies outside the U.S. clinical trial system draws objections from some American health care professionals. They warn of the potential for abuse, say there's a lack of rigorous scientific standards, and call for tighter federal regulation of the proliferation of stem cell treatments.

Nevertheless, patients with ailments that don't response to approved treatments continue to seek such care. These patients and families say they have the right to make their own judgments. And they may not have time to wait for proof, so they're willing to take a chance.

Stemedica says it follows U.S. government law, and requires those licensing its stem cells in foreign countries to obey the laws of those countries.

Follow this link:

Did stem cells really help Gordie Howe?

Aggie grad happy to put off retiring to advance stem cell science

David Eller could have retired a long time ago.

At the age of 76, he could spend his days on permanent vacation fly-fishing in Idaho, golfing in San Antonio or skiing on the Italian-Austrian border like he has done to get away from work for many years.

He isn't working because he is desperate for money and accolades. He's had those for many years.

During the '80s, Eller oversaw revolutionary cattle cloning practices as CEO of Granada BioSciences, a company he founded. He served as chairman of the Texas A&M System Board of Regents from 1983 to 1989. The Oceanography & Meteorology Building on A&M's campus was named in his honor in 1988.In 2000, he was namedexecutive vice president and president of DuPont's European operations.He is president of Eller Holding Company, a privately-held family investment company.

Instead of settling down after a life of amassing great wealth and personal achievement, he co-founded Houston-based Celltex Therapeutics Corporation in 2011 and put himself at the forefront of the contentious issue of autologous stem cell therapy in the name of fighting for ill people to harness the healing properties of their own bodies.

These days it is Celltex that drives Eller's passion, enabling him to combine his humanitarian and entrepreneurial impulses and perhaps one day leave a lasting mark on health care. It is the culmination of the journey he began on the A&M campus in the late 1950s.

"When I started this company I really didn't need another job," Eller said. "I certainly didn't need one with so many rules and regulations we had to adhere to that gives us a lot of headaches. All in all, the biggest reward out of it is seeing people improve their quality of life."

Since 2011, the company has helped treat approximately 600 patients between the ages of 6 and 96 by injecting stem cells taken from their own bodies into a troubled area with no complications, according to Eller. He believes Celltex's reach could expand tenfold if the entire operation could be conducted out of the United States, where the practice was banned in 2012, but that could take years of fighting a two-front war.

The daily war is educating as many doctors and potential patients as possible on the benefits of being treated with a one's own stem cells. The second, long-term war is maneuvering through the FDA's web of red tape that currently bans the practice from being performed on U.S. soil.

Eller spent four years in the Texas A&M Corps of Cadets until his 1959 graduation, which he says plays a major role in his character.

More:

Aggie grad happy to put off retiring to advance stem cell science

Stem Cell Cure: New Therapy For Joint Pain

DALLAS We all get those aches and pains every once in a while. But for some folks, those nagging aches are a pain in the well, you know.

My pain is a variety of different type of pain, David Flory said. In certain parts of the knee, certain types of activities bother it. some dont. Some do.

He has had knee problems since high school and has had five knee surgeries throughout his life.

Now his doctors have told him he needs a total knee replacement, but like a lot of people, Flory didnt want to go through the long recovery time that comes with going under the knife.

So in order to do that, Flory found a doctors office that offers stem cell replacement therapy.

Stem Cells are the type of cells that replicate and become other cells that are used in most healing, said Dr. Bill Johnson with Innovations Medical.

Basically what the doc does is take the stem cells from fat stored on your body, then inject that into the joint. This type of stem cell therapy is still being researched. Dr. Johnson says so far, 85% of knee patients have seen improvement.

Thats improvement to the point where they dont require joint replacement, Dr. Johnson said.

Since the procedure is still in the investigational stage, it isnt covered by insurance and can get a little pricey up to $6,000.

With the investment Im making out-of-pocket, Im hopeful what were doing today will pay off, said Flory.

Originally posted here:

Stem Cell Cure: New Therapy For Joint Pain